Personalis (PSNL) said late Monday that the clinical results of the Predict DNA and Scandare studies showed that its NeXT Personal circulating tumor DNA blood test to monitor neoadjuvant therapy in triple negative breast cancer could identify patients at high risk of relapse.

The test also has the potential to help inform the need for additional therapy, the company said.

Results from the Predict DNA study suggest that ultrasensitive circulating tumor DNA detection in patients with triple-negative breast cancer, after completion of neoadjuvant therapy and prior to surgery, could be used as a prognostic marker, independent of pathologic complete response to guide clinical decision making for additional adjuvant therapies, the company said.